Immunotherapy plus radiation before stomach cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests combining an immunotherapy drug (sintilimab) with low-dose radiation before surgery for stomach cancer that has a specific genetic marker (dMMR/MSI-H). The goal is to see if this combination can shrink the tumor and improve outcomes without needing strong chemo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- Your stomach or junction cancer is locally advanced (spread to nearby lymph nodes but not far away) and can be removed with surgery.
- Your cancer has a specific genetic marker called dMMR or MSI-H.
- You are in good general health (ECOG score 0-1) and have not had any previous cancer treatments like chemo, radiation, or immunotherapy.
- You have adequate organ function (heart, kidney, liver, and blood counts are working well).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests combining chemotherapy (SOX), an immunotherapy drug (tislelizumab), and low-dose radiation before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination shrinks tumors more effectively.
This study tests combining an immunotherapy drug (PD-1 inhibitor) and a medication to boost your immune system (thymalfasin) with standard chemotherapy and radiation before surgery for stage III cancer where the stomach meets the esophagus. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests a new approach for stomach cancer that has spread to nearby tissues but not to other organs. You would get a short course of radiation, followed by a combination of targeted therapy (Disitamab Vedotin), chemotherapy (S-1), and immunotherapy (Sintilimab) before surgery to shrink the tumor and improve outcomes.
This trial tests whether adding the immunotherapy drug sintilimab to two different chemotherapy combinations before surgery can help people with locally advanced gastric cancer that has a specific genetic feature (dMMR). You would receive treatment before surgery to shrink the tumor, then have surgery to remove it.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.